SWOG clinical trial number
CTSU/EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Open
Phase
Abbreviated Title
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients…
Activated
07/13/2015
Participants
CTSU

Research committees

Melanoma

Treatment

Ipilimumab Dabrafenib Nivolumab

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2023

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

M Atkins;S Lee;B Chmielowski;A Tarhini;Moon Truong;D Davar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;A Wolchok;A Ribas;J Kirkwood Journal of Clinical Oncology Jan 10;41(2):186-197

PMid: PMID36166727 | PMC number: PMC9839305

2022

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)

R Jensen;Y Zheng;M Atkins;M Atkins;B Chmielowski;A Tarhini;T Truong;D Davar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;S Lee;A Potosky;J Wolchok;A Ribas;J Kirkwood;L Wagner;D Cella J Clin Oncol 40, 2022 (suppl 16; abstr 9559); American Society of Clinical Oncology

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)

R Jensen;Y Zheng;M Atkins;B Chmielowski;A Tarhini;T-G Truong;D Divar;M O'Rourke;B Curti;J Brell;K Kendra;A Ikeguchi;S Lee;A Potosky;J Wolchok J Clin Oncol 40, 2022 (suppl 16; abstr 9559), poster 152; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

2021

DREAMSeq Trial: Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression VS. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib in Patients with Advanced BRAFV600 Mutant Melanoma (EA6134)

M Atkins;S Lee;B Chmielowski;B Harris;A Ribas;A Tarhini;J Kirkwood ASCO Plenary Series, November 16, 2021, oral

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
91%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase